Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM, Inserm, Inst Neurosci Syst, UMR 1106, Aix-Marseille University, University Hospital Federation DHUNE, 13005 Marseille, France.
Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM, Inserm, Inst Neurosci Syst, UMR 1106, Aix-Marseille University, University Hospital Federation DHUNE, 13005 Marseille, France.
Rev Neurol (Paris). 2023 Nov;179(9):967-974. doi: 10.1016/j.neurol.2023.03.018. Epub 2023 Jul 16.
Cannabis may have therapeutic benefits to relieve symptoms of amyotrophic lateral sclerosis (ALS) thanks to its pleiotropic pharmacological activity. This study is the first to present a large questionnaire-based survey about the "real-life" situation regarding cannabis use in the medical context in ALS patients in France. There were 129 respondents and 28 reported the use of cannabis (21.7%) to relieve symptoms of ALS. Participants mostly reported the use of cannabidiol (CBD) oil and cannabis weed and declared benefits both on motor (rigidity, cramps, fasciculations) and non-motor (sleep quality, pain, emotional state, quality of life, depression) symptoms and only eight reported minor adverse reactions (drowsiness, euphoria and dry mouth). Even if cannabis is mostly used outside medical pathways and could expose patients to complications (street and uncontrolled drugs, drug-drug interactions, adverse effects…), most of the participants reported "rational" consumption (legal cannabinoids, with only few combustion and adverse reactions). Despite some limitations, this study highlights the need for further research on the potential benefits of cannabis use for the management of ALS motor and non-motor symptoms. Indeed, there is an urgent need and call for and from patients to know more about cannabis and secure its use in a medical context.
大麻可能具有治疗益处，可以缓解肌萎缩侧索硬化症（ALS）的症状，这要归功于其多效药理学活性。这项研究首次在法国 ALS 患者的医学背景下，就大麻的“实际”使用情况进行了一项大型基于问卷调查的研究。共有 129 名受访者，其中 28 名报告使用大麻（21.7%）来缓解 ALS 的症状。参与者主要报告使用大麻二酚（CBD）油和大麻草，并宣称对运动（僵硬、痉挛、抽搐）和非运动（睡眠质量、疼痛、情绪状态、生活质量、抑郁）症状都有好处，只有 8 名参与者报告了轻微的不良反应（嗜睡、欣快和口干）。即使大麻主要是在医疗途径之外使用，可能会使患者面临并发症（街头和不受控制的药物、药物相互作用、不良反应等），但大多数参与者报告了“合理”的消费（合法的大麻素，只有少数燃烧和不良反应）。尽管存在一些局限性，但这项研究强调了需要进一步研究大麻使用对 ALS 运动和非运动症状管理的潜在益处。实际上，患者迫切需要和呼吁更多地了解大麻，并确保在医学背景下使用大麻。
